Collectively, these examples indicate that definition of GPER status for patients with breast cancer may help to select patient populations which are best able to respond to existing anti-estrogen therapies, either ovarian suppression, ER antagonism or aromatase inhibitor. Here, CYP19A1 is linked to breast carcinoma.